Association of inflammatory biomarkers with metabolic syndrome in hemodialysis patients

Renal Failure

Volumn 34, Issue 9, 2012, Pages 1109-1113

  Shahrokh, Shabnam ^a   Heydarian, Peimaneh ^b   Ahmadi, Farokhlagha ^a   Saddadi, Fereshteh ^a   Razeghi, Effat ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hemodialysis; HsCRP; Inflammatory biomarkers; Metabolic syndrome

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; FERRITIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH SENSITIVE C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRANSFERRIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; URIC ACID;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; IRAN; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; RENAL DIALYSIS; RISK FACTORS;

EID: 84866354899     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2012.713280     Document Type: Article

References (47)

1. Ucar E, Huzmeli C, Guven O, et al. Frequency of metabolic syndrome among hemodialysis patients according to NCEPATP III and IDF definitions. Ren Fail. 2009;31:221-228.
2. Yang SY, Chiang CK, Hsu SP, et al. Metabolic syndrome predicts hospitalization in hemodialysis patients: A prospective Asian cohort study. Blood Purif. 2007;25:252-259.
3. Rasic-Milutinovic Z, Perunicic G, Pljesa S, et al. Metabolic syndrome in HD patients: Association with body composition, nutritional status, inflammation and serum iron. Intern Med. 2007;46:945-951.
4. Tsangalis G, Papaconstantinou S, Kosmadakis G, et al. Prevalence of the metabolic syndrome in hemodialysis. Int J Artif Organs. 2007;30:118-123.
5. Lee CC, Lee RP, Subeq YM, et al. Fasting serum total ghrelin level inversely correlates with metabolic syndrome in hemodialysis patients. Arch Med Res. 2008;39:785-790.
6. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition. A consensus statement from the international diabetes federation. Diabetes Med. 2006;23:469-480.
7. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-689.
8. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735-2752.
9. Peralta CA, Kurella M, Lo JC, Chertow GM. The metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens. 2006;15:361-365.
10. Shinohara K, Shoji T, Emoto M, et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with endstage renal disease. J Am Soc Nephrol. 2002;13: 1894-1900.
11. Stolic R, Trajkovic G, Jovanovic A, et al. Association of metabolic changes with mortality of patients treated by peritoneal dialysis or hemodialysis. Ren Fail. 2010;32(7):778-783.
12. Mahajan A, Jaiswal A, Tabassum R, et al. Elevated levels of Creactive protein as a risk factor for metabolic syndrome in Indians. Atherosclerosis. 2012;220(1):275-281.
13. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: A new paradigm. Am J Kidney Dis. 2000;35(4 Suppl. 1): S117-S131.
14. Engström G, Lind P, Hedblad B, et al. Lung function and cardiovascular risk: Relationship with inflammation-sensitive plasma proteins. Circulation. 2002;106(20):2555-2560.
15. Razeghi E, Parkhideh S, Ahmadi F. Khashayar 2, serum CRP levels in pre- dialysis, patient. Ren Fail. 2008;30:193-198.
16. Varghese K, Cherian G, Abraham UT, Hayat NJ, Johny KV. Predictors of coronary disease in patients with end stage renal disease. Ren Fail. 2001;23(6):797-806.
17. Rutter MK,Meigs JB, Sullivan LM, et al. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham offspring study. Circulation. 2004;110(4): 380-385.
18. Wilson PWF, D'Agostino RB, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112(20):3066-3072.
19. Ye X, Yu Z, Li H, et al. Distributions of C-reactive protein and its association with metabolic syndrome in middle-aged and older Chinese people. J Am Coll Cardiol. 2007;49(17):798-805.
20. Mahadik SR, Deo SS, Mehtalia SD. Relation of C-reactive protein with the components of metabolic syndrome in Asian Indian subjects. Diabetes Metab Syndr Res Rev. 2008;2(1):29-35.
21. Forouhi NG, Sattar N, McKeigue PM. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obes Relat Metab Disord. 2001;25(9):1327-1331.
22. Festa A, DÁgostino Jr R, Howard G, et al. Chronic subclinical inflammation as a part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102(1):42-47.
23. Frohlich M, Imhof A, Berg G, et al. Association of C-reactive protein and features of metabolic syndrome: A population based study. Diabetes Care. 2000;23(12):1835-1839.
24. Esmaillzadeh A, Mirmiran P, Azadbakht L, Etemadi A, Azizi F. High prevalence of the metabolic syndrome in Iranian adolescents. Obesity. 2006;14(3):377-382.
25. Ghassemi H, Harrison G, Mohammad K. An accelerated nutrition transition in Iran. Public Health Nutr. 2002;5:149-155.
26. Hsu CY, McCulloch CE, Iribarren C, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21-28.
27. Williams JD, Woods HF. Insulin resistance, the metabolic syndrome and renal failure - Is there a special problem for patients treated with peritoneal dialysis? Eur Endocrine Rev. 2006;15:54-59.
28. Bakker SL, Gansevoort RT, Zeeuw DD. Metabolic syndrome: A fata morgana? Nephro Dial Transplant. 2007;22:15-20.
29. Young DO, Lund RJ, Haynatzki G, Dunlay RW. Prevalence of the metabolic syndrome in an incident dialysis population. Hemodial Int. 2007;11:86-95.
30. Armstrong KA, Hiremagalur B, Haluska BA, et al. Free fatty acids are associated with obesity, insulin resistance, and atherosclerosis in renal transplant recipients. Transplantation. 2005;80:937-944.
31. Armstrong KA, Campbell SB, Hawley CM, Nicol DL, Johnson DW, Isbel NM. Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients. Am J Transplant. 2005;5:2710-2718.
32. Elsaid SA, Hamada MA, Alsaran KA. Obesity and metabolic syndrome in Saudi hemodialysis patients. JNRT. 2009;2:18-27.
33. Stoli R, Trajkovi G, Peri V, et al. Frequency and characteristics of metabolic disorders in patients on hemodialysis. Vojnosanit Pregl. 2008;65:205-209.
34. Salmenniemi U, Ruotsalainen E, Pihlajamäki J, et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation. 2004;110:3842-3848.
35. Choi KM, Lee J, Lee KW, et al. Comparison of serum concentrations of C-reactive protein, TNF-alpha, and IL 6 between elderly Korean women with normal and impaired glucose tolerance. Diabetes Res Clin Pract. 2004;64:00.
36. Wisse BE. Inflammatory syndrome: The role of adipose tissue cytokines in metabolic disorders link to obesity. J Am Soc Nephrol. 2004;15:2792-2800.
37. Garg R, Tripathy D, Dandona P. Insulin resistance as a proinflammatory state: Mechanisms, mediators, and therapeutic interventions. Curr Drug Targets. 2003;4:487-492.
38. Collins T, Cybulsky MI. NF-kB: Pivotal mediator or innocent bystander in atherogenesis? J Clin Invest. 2001;107:255-264.
39. Dressner A. Insulin mediated glucose uptake in muscle, in the absence of fatty acids and in the presence of LCFACoA. J Clin Invest. 1999;103:253-259.
40. Feldman HI, Santana J, Guo W, et al. Iron administration and clinical outcome in hemodialysis patients. J Am Soc Nephrol. 2002;13:734-744.
41. Kalantar-Zadeh K, Rodrigez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in hemodialysis patients. Nephrol Dial Transplant. 2004;19:141-149.
42. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Partley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res. 2001;9:414-417.
43. Takeda T, Hoshida S, Nishino M, Tanouchi J, Otsu K, Hori M. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis. 2003;169:155-158.
44. Maeda N, Takahashi M, Funahashi T, et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50:2094-2099.
45. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107:499-511.
46. Hwang SJ, Yang WC, Chen HH, et al. National dialysis surveillance in Taiwan. Acta Nephrol. 1999;14:139-228.
47. Torres JL, Ridker PM. Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. Curr Opin Cardiol. 2003;18:471-478.